Investigating how CASP-11 affects lung problems and immune response after SARS-CoV-2 infection
Official title: Role of CASP-11 in SARS-CoV-2-induced lung pathologies and long-term immune protection
Funded at Ohio State University · NIH-11072973 · Data updated 2026-11-12
This study is looking at how a specific protein called CASP-11 affects lung damage and immune responses in people with COVID-19, especially to help understand why some vaccines might not last long against new variants and how they could lead to ongoing health problems; the goal is to find better ways to treat and support patients during and after their illness.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | April 10, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $429,216 |
| NIH project number | 5P01AI175399-02 |
| Project ID | NIH-11072973 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have experienced COVID-19, particularly those with ongoing symptoms or complications.
✕Less likely to help
Patients who have not been infected with SARS-CoV-2 or those who do not exhibit any symptoms related to COVID-19 may not benefit from this research.
What this research studies
This research focuses on understanding the role of CASP-11 in the lung damage and immune responses associated with SARS-CoV-2 infections. It aims to explore how current vaccines may not provide long-lasting protection against emerging variants and how they can lead to long-term health issues, known as Post-Acute COVID Syndrome (PACS). By studying the inflammatory responses and cytokine release in COVID-19 patients, the research seeks to identify new therapeutic strategies to improve patient outcomes and manage acute infections more effectively.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and vaccines that provide better protection against COVID-19 and its long-term effects.
How similar studies have gone: Previous research has shown that understanding immune responses in viral infections can lead to significant advancements in treatment, indicating potential success for this approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Boyaka, Prosper N — Ohio State University
- Study coordinator: Boyaka, Prosper N
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.